Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance

Nature Neuroscience

Volumn 16, Issue 5, 2013, Pages 562-570

  Lu, Boxun ^a,b   Al Ramahi, Ismael ^c,d   Valencia, Antonio ^e,f   Wang, Qiong ^b   Berenshteyn, Frada ^b   Yang, Haidi ^b   Gallego Flores, Tatiana ^c,d   Ichcho, Salah ^b   Lacoste, Arnaud ^b   Hild, Marc ^b   Difiglia, Marian ^e,f   Botas, Juan ^c,d   Palacino, James ^b  

^a FUDAN UNIVERSITY   (China)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; HUNTINGTIN;

ANIMAL CELL; ARTICLE; DROSOPHILA MELANOGASTER; DRUG MECHANISM; GENE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; NUB1 GENE; PRIORITY JOURNAL; RNA INTERFERENCE; UBIQUITINATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE; CELLS, CULTURED; CULLIN PROTEINS; DISEASE MODELS, ANIMAL; DROSOPHILA; EMBRYO, MAMMALIAN; FEMALE; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEURONS; PREGNANCY; TRANSCRIPTION FACTORS; UBIQUITINS;

EID: 84876917897     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3367     Document Type: Article

References (51)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983 (1993).
2. Cattaneo, E., Zuccato, C. & Tartari, M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930 (2005). (Pubitemid 41753086)
3. Rubinsztein, D.C. & Carmichael, J. Huntington's disease: molecular basis of neurodegeneration. Expert Rev. Mol. Med. 5, 1-21 (2003).
4. Walker, F.O. Huntington's disease. Lancet 369, 218-228 (2007). (Pubitemid 46107685)
5. Landles, C. et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 285, 8808-8823 (2010).
6. Nagashima, Y., Kowa, H., Tsuji, S. & Iwata, A. FAT10 protein binds to polyglutamine proteins and modulates their solubility. J. Biol. Chem. 286, 29594-29600 (2011).
7. Subramaniam, S., Sixt, K.M., Barrow, R. & Snyder, S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324, 1327-1330 (2009).
8. Thompson, L.M. et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187, 1083-1099 (2009).
9. Yamamoto, A., Lucas, J.J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66 (2000).
10. DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. USA 104, 17204-17209 (2007).
11. Harper, S.Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102, 5820-5825 (2005). (Pubitemid 40559643)
12. Rodriguez-Lebron, E., Denovan-Wright, E.M., Nash, K., Lewin, A.S. & Mandel, R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12, 618-633 (2005). (Pubitemid 41350143)
13. Boudreau, R.L. et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 17, 1053-1063 (2009).
14. Drouet, V. et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 65, 276-285 (2009).
15. Bauer, P.O. et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat. Biotechnol. 28, 256-263 (2010).
16. Sarkar, S., Ravikumar, B., Floto, R.A. & Rubinsztein, D.C. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16, 46-56 (2009).
17. Filimonenko, M. et al. The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy. Mol. Cell 38, 265-279 (2010).
18. Jana, N.R. et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 280, 11635-11640 (2005). (Pubitemid 40418477)
19. Kaltenbach, L.S. et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 3, e82 (2007).
20. Shirasaki, D.I. et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 75, 41-57 (2012).
21. Doumanis, J., Wada, K., Kino, Y., Moore, A.W. & Nukina, N. RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation. PLoS ONE 4, e7275 (2009).
22. Zhang, S., Binari, R., Zhou, R. & Perrimon, N. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 184, 1165-1179 (2010).
23. Miller, J.P. et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 67, 199-212 (2010).
24. Bauer, P.O. & Nukina, N. Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy 5, 747-748 (2009).
25. Brand, A.H. & Perrimon, N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118, 401-415 (1993). (Pubitemid 23214028)
26. Tanji, K. et al. NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1. Am. J. Pathol. 169, 553-565 (2006). (Pubitemid 44156314)
27. Kito, K., Yeh, E.T. & Kamitani, T. NUB1, a NEDD8-interacting protein, is induced by interferon and down-regulates the NEDD8 expression. J. Biol. Chem. 276, 20603-20609 (2001).
28. Baldo, B. et al. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease. Chem. Biol. 19, 264-275 (2012).
29. Gutekunst, C.A. et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19, 2522-2534 (1999).
30. Lu, B. & Palacino, J. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J . doi:10.1096/fj.12- 219220 (16 January 2013).
31. The HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11, 264-278 (2012).
32. Kamitani, T., Kito, K., Fukuda-Kamitani, T. & Yeh, E.T. Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1. J. Biol. Chem. 276, 46655-46660 (2001).
33. Tanaka, T., Kawashima, H., Yeh, E.T. & Kamitani, T. Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J. Biol. Chem. 278, 32905-32913 (2003). (Pubitemid 37055733)
34. Hipp, M.S., Raasi, S., Groettrup, M. & Schmidtke, G. NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J. Biol. Chem. 279, 16503-16510 (2004). (Pubitemid 38509349)
35. Soucy, T.A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
36. Chew, E.H. & Hagen, T. Substrate-mediated regulation of cullin neddylation. J. Biol. Chem. 282, 17032-17040 (2007). (Pubitemid 47093199)
37. Paty, D.W., Li, D.K. & the UBC MS/MRI Study Group & the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 662-667 (1993). (Pubitemid 23121952)
38. MacDonald, M.E. et al. Targeted inactivation of the mouse Huntington's disease gene homolog Hdh. Cold Spring Harb. Symp. Quant. Biol. 61, 627-638 (1996).
39. Duyao, M.P. et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269, 407-410 (1995).
40. Grondin, R. et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197-1209 (2012).
41. Tanji, K. et al. Immunohistochemical localization of NUB1, a synphilin-1-binding protein, in neurodegenerative disorders. Acta Neuropathol. 114, 365-371 (2007). (Pubitemid 47500348)
42. Weiss, A., Roscic, A. & Paganetti, P. Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction. Mol. Neurodegener. 4, 11 (2009).
43. Lacoste, A., Berenshteyn, F. & Brivanlou, A.H. An efficient and reversible transposable system for gene delivery and lineage-specific differentiation in human embryonic stem cells. Cell Stem Cell 5, 332-342 (2009).
44. Chambers, S.M. et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275-280 (2009).
45. Ko, J., Ou, S. & Patterson, P.H. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 56, 319-329 (2001). (Pubitemid 33062356)
46. Weiss, A. et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal. Biochem. 395, 8-15 (2009).
47. Weiss, A. et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J. Clin. Invest. 122, 3731-3736 (2012).
48. Al-Ramahi, I. et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J. Biol. Chem. 281, 26714-26724 (2006). (Pubitemid 44401880)
49. Menalled, L.B., Sison, J.D., Dragatsis, I., Zeitlin, S. & Chesselet, M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465, 11-26 (2003). (Pubitemid 37075677)
50. Valencia, A. et al. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J. Neurosci. Res. 88, 179-190 (2010).
51. Liew, C.W. et al. The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells. J. Clin. Invest. 120, 2876-2888 (2010).